Cargando…
Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomark...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/ https://www.ncbi.nlm.nih.gov/pubmed/36799816 http://dx.doi.org/10.1097/JS9.0000000000000200 |
_version_ | 1785082274026356736 |
---|---|
author | Cui, Ming Shoucair, Sami Liao, Quan Qiu, Xiaoyan Kinny-Köster, Benedict Habib, Joseph R. Ghabi, Elie M. Wang, Junke Shin, Eun Ji Leng, Sean X. Ali, Syed Z. Thompson, Elizabeth D. Zimmerman, Jacquelyn W. Shubert, Christopher R. Lafaro, Kelly J. Burkhart, Richard A. Burns, William R. Zheng, Lei He, Jin Zhao, Yupei Wolfgang, Christopher L. Yu, Jun |
author_facet | Cui, Ming Shoucair, Sami Liao, Quan Qiu, Xiaoyan Kinny-Köster, Benedict Habib, Joseph R. Ghabi, Elie M. Wang, Junke Shin, Eun Ji Leng, Sean X. Ali, Syed Z. Thompson, Elizabeth D. Zimmerman, Jacquelyn W. Shubert, Christopher R. Lafaro, Kelly J. Burkhart, Richard A. Burns, William R. Zheng, Lei He, Jin Zhao, Yupei Wolfgang, Christopher L. Yu, Jun |
author_sort | Cui, Ming |
collection | PubMed |
description | Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomarker in PDAC. This study aims to explore whether SIA-IgG expression in treatment-naïve fine needle aspirate (FNA) biopsy specimens could predict the pathological response (PR) to NAT for PDAC. METHODS: Endoscopic ultrasonography-guided FNA biopsy specimens prior to NAT were prospectively obtained from 72 patients with PDAC at the Johns Hopkins Hospital. SIA-IgG expression of PDAC specimens was assessed by immunohistochemistry. Associations between SIA-IgG expression and PR, as well as patient prognosis, were analyzed. A second cohort enrolling surgically resected primary tumor specimens from 79 patients with PDAC was used to validate the prognostic value of SIA-IgG expression. RESULTS: SIA-IgG was expressed in 58.3% of treatment-naïve FNA biopsies. Positive SIA-IgG expression at diagnosis was associated with unfavorable PR and can serve as an independent predictor of PR. The sensitivity and specificity of SIA-IgG expression in FNA specimens in predicting an unfavorable PR were 63.9% and 80.6%, respectively. Both positive SIA-IgG expression in treatment-naïve FNA specimens and high SIA-IgG expression in surgically resected primary tumor specimens were significantly associated with shorter survival. CONCLUSIONS: Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC. |
format | Online Article Text |
id | pubmed-10389326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-103893262023-08-01 Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer Cui, Ming Shoucair, Sami Liao, Quan Qiu, Xiaoyan Kinny-Köster, Benedict Habib, Joseph R. Ghabi, Elie M. Wang, Junke Shin, Eun Ji Leng, Sean X. Ali, Syed Z. Thompson, Elizabeth D. Zimmerman, Jacquelyn W. Shubert, Christopher R. Lafaro, Kelly J. Burkhart, Richard A. Burns, William R. Zheng, Lei He, Jin Zhao, Yupei Wolfgang, Christopher L. Yu, Jun Int J Surg Original Research Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomarker in PDAC. This study aims to explore whether SIA-IgG expression in treatment-naïve fine needle aspirate (FNA) biopsy specimens could predict the pathological response (PR) to NAT for PDAC. METHODS: Endoscopic ultrasonography-guided FNA biopsy specimens prior to NAT were prospectively obtained from 72 patients with PDAC at the Johns Hopkins Hospital. SIA-IgG expression of PDAC specimens was assessed by immunohistochemistry. Associations between SIA-IgG expression and PR, as well as patient prognosis, were analyzed. A second cohort enrolling surgically resected primary tumor specimens from 79 patients with PDAC was used to validate the prognostic value of SIA-IgG expression. RESULTS: SIA-IgG was expressed in 58.3% of treatment-naïve FNA biopsies. Positive SIA-IgG expression at diagnosis was associated with unfavorable PR and can serve as an independent predictor of PR. The sensitivity and specificity of SIA-IgG expression in FNA specimens in predicting an unfavorable PR were 63.9% and 80.6%, respectively. Both positive SIA-IgG expression in treatment-naïve FNA specimens and high SIA-IgG expression in surgically resected primary tumor specimens were significantly associated with shorter survival. CONCLUSIONS: Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC. Lippincott Williams & Wilkins 2023-02-16 /pmc/articles/PMC10389326/ /pubmed/36799816 http://dx.doi.org/10.1097/JS9.0000000000000200 Text en © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Research Cui, Ming Shoucair, Sami Liao, Quan Qiu, Xiaoyan Kinny-Köster, Benedict Habib, Joseph R. Ghabi, Elie M. Wang, Junke Shin, Eun Ji Leng, Sean X. Ali, Syed Z. Thompson, Elizabeth D. Zimmerman, Jacquelyn W. Shubert, Christopher R. Lafaro, Kelly J. Burkhart, Richard A. Burns, William R. Zheng, Lei He, Jin Zhao, Yupei Wolfgang, Christopher L. Yu, Jun Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title | Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title_full | Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title_fullStr | Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title_full_unstemmed | Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title_short | Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
title_sort | cancer-cell-derived sialylated igg as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/ https://www.ncbi.nlm.nih.gov/pubmed/36799816 http://dx.doi.org/10.1097/JS9.0000000000000200 |
work_keys_str_mv | AT cuiming cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT shoucairsami cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT liaoquan cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT qiuxiaoyan cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT kinnykosterbenedict cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT habibjosephr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT ghabieliem cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT wangjunke cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT shineunji cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT lengseanx cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT alisyedz cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT thompsonelizabethd cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT zimmermanjacquelynw cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT shubertchristopherr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT lafarokellyj cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT burkhartricharda cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT burnswilliamr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT zhenglei cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT hejin cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT zhaoyupei cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT wolfgangchristopherl cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer AT yujun cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer |